New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin hydrochloride 832.5mg equivalent to ciprofloxacin 750 mg (anhydrous);   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 832.5mg equivalent to ciprofloxacin 750 mg (anhydrous)   excipient: colloidal silicon dioxide crospovidone hypromellose macrogols magnesium stearate maize starch microcrystalline cellulose opadry white y-22-7719 polydextrose pregelatinised maize starch purified water titanium dioxide triacetin - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg;  ;   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg     excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg;  ;   - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg     excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg;  ;   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg     excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate - film coated tablet - 100 mg - active: ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 10 g - oral suspension - 100 mg/ml - active: ciprofloxacin 10 g excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin - oral suspension - 50 mg/ml - active: ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose